Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

NCT04853368 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Cystic Fibrosis (CF)

Interventions

DRUG: ABBV-576
DRUG: Galicaftor
DRUG: Placebo
DRUG: Navocaftor
DRUG: ABBV-119

Sponsor

AbbVie